APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tofacitinib Citrate Extended-Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tofacitinib Citrate Extended-Release Tablets Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchTofacitinib Citrate Extended-Release Tablets Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Tofacitinib Citrate Extended-Release Tablets Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Tofacitinib Citrate Extended-Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tofacitinib Citrate Extended-Release Tablets Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tofacitinib Citrate Extended-Release Tablets Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Tofacitinib Citrate Extended-Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tofacitinib Citrate Extended-Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tofacitinib Citrate Extended-Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tofacitinib Citrate Extended-Release Tablets market include Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lepu Pharmaceutical, Sino Therapeutics, Zydus and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tofacitinib Citrate Extended-Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tofacitinib Citrate Extended-Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tofacitinib Citrate Extended-Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tofacitinib Citrate Extended-Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Tofacitinib Citrate Extended-Release Tablets Segment by Company

Yichang Humanwell Pharmaceutical

Sichuan Kelun Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lepu Pharmaceutical

Sino Therapeutics

Zydus

Pfizer

Tofacitinib Citrate Extended-Release Tablets Segment by Type

11mg per Tablet

22mg per Tablet

Tofacitinib Citrate Extended-Release Tablets Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Ulcerative Colitis

Other

Tofacitinib Citrate Extended-Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tofacitinib Citrate Extended-Release Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tofacitinib Citrate Extended-Release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tofacitinib Citrate Extended-Release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Tofacitinib Citrate Extended-Release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tofacitinib Citrate Extended-Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tofacitinib Citrate Extended-Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tofacitinib Citrate Extended-Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tofacitinib Citrate Extended-Release Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tofacitinib Citrate Extended-Release Tablets industry.

Chapter 3: Detailed analysis of Tofacitinib Citrate Extended-Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tofacitinib Citrate Extended-Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tofacitinib Citrate Extended-Release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tofacitinib Citrate Extended-Release Tablets Industry Trends Table 2. Tofacitinib Citrate Extended-Release Tablets Industry Drivers Table 3. Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges Table 4. Tofacitinib Citrate Extended-Release Tablets Industry Restraints Table 5. Global Tofacitinib Citrate Extended-Release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tofacitinib Citrate Extended-Release Tablets Revenue Share by Company (2021-2026) Table 7. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Tofacitinib Citrate Extended-Release Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Tofacitinib Citrate Extended-Release Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tofacitinib Citrate Extended-Release Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Tofacitinib Citrate Extended-Release Tablets Company, Product Type & Application Table 13. Global Tofacitinib Citrate Extended-Release Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tofacitinib Citrate Extended-Release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 11mg per Tablet Table 18. Significant Companies of 22mg per Tablet Table 19. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type (2021-2026) Table 28. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Rheumatoid Arthritis Table 30. Significant Companies of Psoriatic Arthritis Table 31. Significant Companies of Ankylosing Spondylitis Table 32. Significant Companies of Ulcerative Colitis Table 33. Significant Companies of Other Table 34. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Application (2021-2026) Table 38. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Application (2027-2032) Table 39. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application (2021-2026) Table 43. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application (2027-2032) Table 44. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2026) & (K Units) Table 46. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2021-2026) Table 47. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2027-2032) & (K Units) Table 48. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region (2027-2032) Table 49. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Region (2021-2026) Table 52. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Region (2027-2032) Table 54. Global Tofacitinib Citrate Extended-Release Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Tofacitinib Citrate Extended-Release Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Tofacitinib Citrate Extended-Release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026) & (K Units) Table 59. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2021-2026) Table 60. Global Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032) & (K Units) Table 61. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Country (2027-2032) Table 62. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Market Share by Country (2021-2026) Table 64. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Market Share by Country (2027-2032) Table 66. Yichang Humanwell Pharmaceutical Company Information Table 67. Yichang Humanwell Pharmaceutical Business Overview Table 68. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 70. Yichang Humanwell Pharmaceutical Recent Development Table 71. Sichuan Kelun Pharmaceutical Company Information Table 72. Sichuan Kelun Pharmaceutical Business Overview Table 73. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 75. Sichuan Kelun Pharmaceutical Recent Development Table 76. CSPC Ouyi Pharmaceutical Company Information Table 77. CSPC Ouyi Pharmaceutical Business Overview Table 78. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 80. CSPC Ouyi Pharmaceutical Recent Development Table 81. Qilu Pharmaceutical Company Information Table 82. Qilu Pharmaceutical Business Overview Table 83. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 85. Qilu Pharmaceutical Recent Development Table 86. Lepu Pharmaceutical Company Information Table 87. Lepu Pharmaceutical Business Overview Table 88. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 90. Lepu Pharmaceutical Recent Development Table 91. Sino Therapeutics Company Information Table 92. Sino Therapeutics Business Overview Table 93. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 95. Sino Therapeutics Recent Development Table 96. Zydus Company Information Table 97. Zydus Business Overview Table 98. Zydus Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 100. Zydus Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Tofacitinib Citrate Extended-Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio Table 105. Pfizer Recent Development Table 106. Key Raw Materials Table 107. Raw Materials Key Suppliers Table 108. Tofacitinib Citrate Extended-Release Tablets Distributors List Table 109. Tofacitinib Citrate Extended-Release Tablets Customers List Table 110. Research Programs/Design for This Report Table 111. Authors List of This Report Table 112. Secondary Sources Table 113. Primary Sources List of Figures Figure 1. Tofacitinib Citrate Extended-Release Tablets Product Image Figure 2. Global Tofacitinib Citrate Extended-Release Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tofacitinib Citrate Extended-Release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Tofacitinib Citrate Extended-Release Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Tofacitinib Citrate Extended-Release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 11mg per Tablet Image Figure 10. 22mg per Tablet Image Figure 11. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type (2021-2032) Figure 17. Rheumatoid Arthritis Image Figure 18. Psoriatic Arthritis Image Figure 19. Ankylosing Spondylitis Image Figure 20. Ulcerative Colitis Image Figure 21. Other Image Figure 22. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Application (2021-2032) Figure 25. Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application (2021-2032) Figure 28. Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Tofacitinib Citrate Extended-Release Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 33. North America Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 39. South America Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Tofacitinib Citrate Extended-Release Tablets Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Tofacitinib Citrate Extended-Release Tablets Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 11mg per Tablet
  • 22mg per Tablet
Applications
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Ulcerative Colitis
  • Other
Companies covered
  • Yichang Humanwell Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Lepu Pharmaceutical
  • Sino Therapeutics
  • Zydus
  • Pfizer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tofacitinib Citrate Extended-Release Tablets Market Dynamics
  1. 2.1 Tofacitinib Citrate Extended-Release Tablets Industry Trends
  2. 2.2 Tofacitinib Citrate Extended-Release Tablets Industry Drivers
  3. 2.3 Tofacitinib Citrate Extended-Release Tablets Industry Opportunities and Challenges
  4. 2.4 Tofacitinib Citrate Extended-Release Tablets Industry Restraints
3 Tofacitinib Citrate Extended-Release Tablets Market by Company
  1. 3.1 Global Tofacitinib Citrate Extended-Release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Tofacitinib Citrate Extended-Release Tablets Company Ranking (2024-2026)
  6. 3.6 Global Tofacitinib Citrate Extended-Release Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Tofacitinib Citrate Extended-Release Tablets Company Product Type and Application
  8. 3.8 Global Tofacitinib Citrate Extended-Release Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tofacitinib Citrate Extended-Release Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tofacitinib Citrate Extended-Release Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tofacitinib Citrate Extended-Release Tablets Market by Type
  1. 4.1 Tofacitinib Citrate Extended-Release Tablets Type Introduction
  2. 4.1.1 11mg per Tablet
  3. 4.1.2 22mg per Tablet
  4. 4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type
  5. 4.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type
  9. 4.3.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type (2021-2032)
5 Tofacitinib Citrate Extended-Release Tablets Market by Application
  1. 5.1 Tofacitinib Citrate Extended-Release Tablets Application Introduction
  2. 5.1.1 Rheumatoid Arthritis
  3. 5.1.2 Psoriatic Arthritis
  4. 5.1.3 Ankylosing Spondylitis
  5. 5.1.4 Ulcerative Colitis
  6. 5.1.5 Other
  7. 5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application
  8. 5.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application
  12. 5.3.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Application (2021-2032)
  14. 5.3.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application (2021-2032)
6 Tofacitinib Citrate Extended-Release Tablets Regional Sales and Value Analysis
  1. 6.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Region (2027-2032)
  5. 6.3 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Tofacitinib Citrate Extended-Release Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Country, 2025 VS 2032
7 Tofacitinib Citrate Extended-Release Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Tofacitinib Citrate Extended-Release Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Tofacitinib Citrate Extended-Release Tablets Sales by Country (2027-2032)
  6. 7.4 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tofacitinib Citrate Extended-Release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yichang Humanwell Pharmaceutical
  2. 8.1.1 Yichang Humanwell Pharmaceutical Company Information
  3. 8.1.2 Yichang Humanwell Pharmaceutical Business Overview
  4. 8.1.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  6. 8.1.5 Yichang Humanwell Pharmaceutical Recent Developments
  7. 8.2 Sichuan Kelun Pharmaceutical
  8. 8.2.1 Sichuan Kelun Pharmaceutical Company Information
  9. 8.2.2 Sichuan Kelun Pharmaceutical Business Overview
  10. 8.2.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  12. 8.2.5 Sichuan Kelun Pharmaceutical Recent Developments
  13. 8.3 CSPC Ouyi Pharmaceutical
  14. 8.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 8.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 8.3.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  18. 8.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Lepu Pharmaceutical
  26. 8.5.1 Lepu Pharmaceutical Company Information
  27. 8.5.2 Lepu Pharmaceutical Business Overview
  28. 8.5.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  30. 8.5.5 Lepu Pharmaceutical Recent Developments
  31. 8.6 Sino Therapeutics
  32. 8.6.1 Sino Therapeutics Company Information
  33. 8.6.2 Sino Therapeutics Business Overview
  34. 8.6.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  36. 8.6.5 Sino Therapeutics Recent Developments
  37. 8.7 Zydus
  38. 8.7.1 Zydus Company Information
  39. 8.7.2 Zydus Business Overview
  40. 8.7.3 Zydus Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  42. 8.7.5 Zydus Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tofacitinib Citrate Extended-Release Tablets Value Chain Analysis
  2. 9.1.1 Tofacitinib Citrate Extended-Release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tofacitinib Citrate Extended-Release Tablets Sales Mode & Process
  6. 9.2 Tofacitinib Citrate Extended-Release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tofacitinib Citrate Extended-Release Tablets Distributors
  9. 9.2.3 Tofacitinib Citrate Extended-Release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst